Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Analgesic Efficacy of Blocking Nerve to Vastus Lateralis Muscle Versus Lateral Femoral Cutaneous Nerve After Knee Surgeries

NCT06809842 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-02-05
Last updated
2025-02-06

Condition(s) studied

AnalgesiaVastus Lateralis Nerve BlockLateral Femoral Cutaneous Nerve BlockKnee Surgeries

Investigational drug(s) / intervention(s)

Vastus lateralis nerve block →Lateral femoral cutaneous nerve block →

Vastus lateralis nerve block: Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.

Lateral femoral cutaneous nerve block: Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.

Study summary

This study aims to compare the analgesic efficacy and functional outcomes of blocking the nerve to the vastus lateralis (NVL) muscle versus the lateral femoral cutaneous nerve (LFCN).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status from I to III. * Underwent knee surgeries under spinal anesthesia. Exclusion Criteria: * Pregnancy. * Coagulopathy. * Neuromuscular disorders. * Hematological disorders. * Mental disorders. * History of multiple traumas or anesthesia drug allergies. * Local skin infection at the block site. * Body mass index (BMI) greater than 40. * Opioid analgesics or abusing opioids.

Primary outcome measure(s)

  • Degree of pain — 24 hours postoperatively
    Each patient will be instructed about postoperative pain assessment using the numeric rating scale (NRS) score (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS assessments will be conducted at the post-anesthesia care unit (PACU) and at 2, 4, 6, 12, 18, and 24 hours postoperatively.

Trial sites (1)

FacilityCityRegionStatus
Kafrelsheikh University Kafr ash Shaykh Kafrelsheikh Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06809842 on ClinicalTrials.gov ↗ ← All trials in Egypt